BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

If left untreated, it can progress to more severe conditions like cirrhosis or liver cancer. The main cause of fatty liver is the accumulation of triglycerides in liver cells. This buildup can ...

Ultimately, this leads to patients who at one time might have been in a window for LT no longer being candidates or the indication being liver dysfunction because of a burned-out liver. Thus, we are ...

Doctors have said the combination of both diseases is dangerous, as it raises the risk of serious complications like heart disease, kidney failure, liver cancer, and stroke. To tackle this growing ...

Furthermore, we extended this exemplar to other models of virus-associated cancer. Design and results Clinical grade oncolytic orthoreovirus (Reo) elicited innate immune activation within primary ...

Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases ... Italian Ministry of Health and Alliance Against ...

Kardashian thanked her “blessing” of a doctor, Garth Fischer, for being able to remove the skin cancer in the first place, adding that he removed the mass “so carefully.” The podcast host ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income ...